Gilead Sciences · 1 day ago
Scientist, Inflammation
Gilead Sciences is dedicated to creating a healthier world and is seeking a talented Scientist to join their inflammation group. The successful candidate will focus on the discovery and development of immunotherapeutic agents for inflammatory diseases and will work collaboratively on multidisciplinary project teams.
BiopharmaBiotechnologyHealth CareManufacturingPharmaceutical
Responsibilities
Responsible for designing and executing scientific research for the discovery of drug targets, the development of drug candidates, and the identification and validation of drug combinations
Independently designs, conducts, analyzes in vitro and in vivo experiments to support the initiation and/or advancement of drug candidates
Works collaboratively in cross-functional project teams
Proactively evaluates new technologies and develop new assays to enhance our understanding of disease mechanisms
Capable of preparing technical study reports, INDs, and patent applications
Excellent communication skills (both written and verbal) and interpersonal skills are required
Must think critically and creatively, stay informed of the latest developments in the field, and have strong organizational and planning skills
Qualification
Required
6+ Years with BS OR
4+ Years with MS OR
0+ Years with PhD/PharmD
Responsible for designing and executing scientific research for the discovery of drug targets, the development of drug candidates, and the identification and validation of drug combinations
Independently designs, conducts, analyzes in vitro and in vivo experiments to support the initiation and/or advancement of drug candidates
Works collaboratively in cross-functional project teams
Proactively evaluates new technologies and develop new assays to enhance our understanding of disease mechanisms
Capable of preparing technical study reports, INDs, and patent applications
Excellent communication skills (both written and verbal) and interpersonal skills are required
Must think critically and creatively, stay informed of the latest developments in the field, and have strong organizational and planning skills
Preferred
PhD & 2 years of experience preferred
Preference will be given to candidates with a strong background and hands-on experience in human immunology, inflammatory diseases, or immune modulation strategies
Experience with mouse pre-clinical models of disease is preferred. Preference will be given to candidates with mouse handling experience and in-vivo techniques
Demonstrated experience in target discovery, translational research, and drug development is preferred
Subject matter expertise in the evaluation of large molecule therapeutics is preferred PhD or equivalent degree and at least 2 years of relevant post-PhD research experience, or drug development experience in immunology/inflammation
The individual will have demonstrable skills and experience in leading focused hypothesis-driven biological research, as exemplified by quality publications
The successful candidate must have demonstrated success in working in a cross-functional and highly collaborative team environment, and to communicate clearly and effectively in both verbally and in writing to a variety of audiences
Benefits
Discretionary annual bonus
Discretionary stock-based long-term incentives (eligibility may vary based on role)
Paid time off
Company-sponsored medical, dental, vision, and life insurance plans
Company
Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases.
H1B Sponsorship
Gilead Sciences has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (269)
2024 (241)
2023 (222)
2022 (208)
2021 (235)
2020 (187)
Funding
Current Stage
Public CompanyTotal Funding
$4.41BKey Investors
Abingworth
2024-11-13Post Ipo Debt· $3.5M
2024-02-29Post Ipo Equity· $210M
2023-09-07Post Ipo Debt· $2B
Leadership Team
Recent News
2026-01-06
MarketScreener
2026-01-06
Company data provided by crunchbase